Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study.
Whi-An KwonJae Young JoungJung Eun LeeSe Young ChoiSung Han KimHo Kyung SeoKang Hyun LeeChoung-Soo KimPublished in: Investigative and clinical urology (2019)
Comparing our findings with those of the prior chemohormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer (CHAARTED) study, in Korean patients, the use of docetaxel plus ADT for mHSPC showed similar results for early oncologic outcomes including PSA response and time to clinical progression. However, we observed a higher rate of adverse events, which should be considered seriously.
Keyphrases
- prostate cancer
- end stage renal disease
- radical prostatectomy
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- type diabetes
- stem cells
- mesenchymal stem cells
- patient reported outcomes
- locally advanced
- skeletal muscle
- atrial fibrillation
- rectal cancer
- catheter ablation